Activating the Immune System to Fight COVID-19
CPI-006 is an immunomodulatory antibody that binds to immune cells, leading to activation of B cells and antibody production that we believe will destroy the SARS-CoV-2 virus.
This therapy has the potential to be used in mild or moderately ill COVID-19 patients as well as in healthy people to enhance the efficacy of vaccines.
Increasing the immune response to the COVID-19 infection may lead to faster viral clearance, shorter recovery time, less complications and longer lasting immunity
This approach has the potential to be a foundational therapy for SARS-CoV-2 mutant variants, other coronaviruses or future pandemics
COVID-19 Publication
The following contains links to certain websites owned and operated by third parties. If you use these links you leave our website. These links are provided for your information and convenience only and are not an endorsement by Corvus Pharmaceuticals, Inc. of the content of such linked websites. Corvus has no control of the content of any linked website and is not responsible for these websites or their content or availability. Corvus therefore makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by or the information contained on them.
Stephen B. Willingham, Gerard Criner, Craig Hill, Shenshen Hu, Jenny A. Rudnick, Barbara Daine-Matsuoka, Jessica Hsieh, Haider Mashhedi, Andrew N. Hotson, Joshua Brody, Thomas Marron, Emily Piccione, Joseph J. Buggy, Suresh Mahabhashyam, William B. Jones, Mehrdad Mobasher, and Richard A. Miller
medRxiv doi: 10.1101/2020.09.10.20191486
Our Science
We are developing oncology medicines with differentiated mechanisms of action directed at precisely-defined molecular targets
Join Our Team
Contribute your talent, expertise and desire to learn here at Corvus, where you can help improve the lives of people with cancer
